Tartrate of selective CDK9 inhibitor and crystal form thereof
US11566024B2 · kind B2 · utility
0Cited by
0References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 29, 2019 |
| Grant date | Jan 31, 2023 |
| Priority date | — |
| Expiry date | Jun 29, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are a tartrate of 3-(5-fluoro-4-(4-methyl-2-(methylamino)thiazol-5-yl) pyrimidin-2-ylamino)-benzenesulfonamide and a polymorph thereof, which are inhibitors of protein kinases, in particular cyclin-dependent kinase 9 (CDK9), and can be used to treat proliferative disorders, such as cancer, and other diseases related to protein kinase/CDK activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.